SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA - Sarafidis, P; Ferro, CJ; Morales, E (Nephrol Dial Transplant, 2019)